Pancreatic Cancer Research

ResearcherNorth Sichuan Medical UniversityActive in the last 2 years

Dawei Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5602-4795; OpenAlex author ID A5102988721, A5103472994. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 11

  1. Individualized treatment and key prognostic biomarkers based on folate metabolism in patients with pancreatic cancer. Last author DOI 10.21037/tcr-2025-2070↗
  2. Phenylalanine Hydroxylase as a Prognostic Marker in Pancreatic Cancer: Insights into Tumor Metabolism and Immune Microenvironment. Last author DOI 10.2174/0109298673470145260529120516↗
  3. Prognostic Value of TBC1D1 and Its Relationship With the Tumor Microenvironment in Pancreatic Cancer: A Study Based on Single-Cell Sequencing. Co-author DOI 10.1096/fba.2025-00092↗
  4. One-carbon metabolic reprogramming and its relationship with tumor-infiltrating lymphocytes and Immune checkpoint in Pancreatic cancer Co-author DOI 10.21203/rs.3.rs-6404670/v1↗
  5. Risk and prognostic factors of survival for patients with pancreatic ductal adenocarcinoma metastasis to lung: a cohort study. Co-author DOI 10.3389/fonc.2025.1521616↗
  6. Multi-Omics Profiling Reveals Glycerolipid Metabolism-Associated Molecular Subtypes and Identifies ALDH2 as a Prognostic Biomarker in Pancreatic Cancer. Co-author DOI 10.3390/metabo15030207↗
  7. Letter to the Editor 'Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in … Co-author DOI 10.1097/js9.0000000000001654↗
  8. High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1341209↗
  9. Catenin delta 1 mediates epithelial–mesenchymal transition, proliferation, migration, and invasion of pancreatic cancer via the Wnt/β-catenin pathway Co-author DOI 10.21203/rs.3.rs-1976828/v1↗
  10. DOK1/3/6 Serve as Potential Prognostic Biomarkers and Immunotherapy Targets for Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-907920/v1↗
  11. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Net… Co-author DOI 10.3389/fgene.2021.692953↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chuan Lan · 4 shared papers, 2022–2025 · strength 0.80
  2. Peng Yi · 3 shared papers, 2025–2026 · strength 0.79
  3. Guangnian Zhang · 3 shared papers, 2022–2025 · strength 0.55
  4. Jianshui Li · 3 shared papers, 2022–2025 · strength 0.55
  5. Dong Shang · 2 shared papers, 2021–2025 · strength 0.43
  6. Jun Qing Yu · 2 shared papers, 2024–2025 · strength 0.42
  7. Yong Li · 2 shared papers, 2024–2025 · strength 0.42
  8. Qihang Yuan · 2 shared papers, 2021–2025 · strength 0.40
  9. Hanfeng Yang · 1 shared paper, 2024 · strength 0.31
  10. Duan Yan · 1 shared paper, 2026 · strength 0.30
  11. Liu Y · 1 shared paper, 2026 · strength 0.30
  12. Jifeng Liu · 1 shared paper, 2025 · strength 0.27
  13. Peiyuan Yin · 1 shared paper, 2025 · strength 0.27
  14. Linfeng Yang · 1 shared paper, 2025 · strength 0.25
  15. Yi Chen · 1 shared paper, 2025 · strength 0.22
  16. Yifu Hou · 1 shared paper, 2024 · strength 0.20
  17. Dongmei Ren · 1 shared paper, 2024 · strength 0.20
  18. Zhizhou Wang · 1 shared paper, 2021 · strength 0.16
  19. Ji Li · 1 shared paper, 2021 · strength 0.16
  20. Fangyue Guo · 1 shared paper, 2021 · strength 0.15
  21. Dong Shang · 1 shared paper, 2021 · strength 0.15
  22. Xiaobin Huang · 1 shared paper, 2022 · strength 0.13
  23. Jun Yu · 1 shared paper, 2022 · strength 0.13
  24. Xingyu Liu · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.